Table 11.

Clinical trials for growth factors.

Clinical trial #	Clinical trial title	Intervention	Characteristics
			Enrollment	Model	Allocation	Phase
NCT00812513	Efficacy of R-Pdf/Gbb in healing wounds caused by third degree thermal and electrical burns	Drug: Recombinant Human PDGF	120	SGA	–	2
NCT01553708	Effect of EGF with silver sulfadiazine cream compared with silver zinc sulfadiazine cream for treatment of burn wound	Drug: EGF with silver sulfadiazine cream Drug: Silver zinc sulfadiazine cream	34	PA	R	2, 3
NCT03279549	Research on the key technology of burn wound treatment	Procedure: Routine dressing change Procedure: Limited debridement (LD) & ADM dressing Procedure: LD & Epidermal cell spraying Procedure: LD & bFGF	200	PA	R	–
NCT01843686	Using autologous platelet rich plasma (PRP) gel to treat deep 2nd and 3rd degree burns	Device: Magellan® Other: Placebo Saline Gel and Usual and SOC	42	PA	R	1
NCT01383187	Autologous platelets concentrate and autologous thrombin for the treatment of deep burn trauma	Procedure: Autograft and PRP concentrate Procedure: Autograft	30	PA	NR	2, 3
NCT02169362	Applying platelet rich plasma (PRP) gel to acute deep partial thickness thermal injuries	Device: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)	36	SGA	R	1
NCT00858442	Platelet-rich plasma (PRP) in reconstructive surgery on children with retractable burn sequelae on extremities	Procedure: With PRP	44	PA	R	–
NCT00856934	Effect of platelet rich plasma and keratinocyte suspensions on wound healing	Biological: Autologous Platelet Rich Plasma Biological: Keratinocyte suspension Other: Standard dressings	45	PA	R	1

–, study did not mention; ADM, Acellular Dermal Matrix; SOC, Standard of Care; STSG, Split-Thickness Skin Graft. Model: PA, Parallel Assignment (Therapy vs. SOC); SGA, Single Group Assignment. Allocation: R, Randomized; NR, Non-Randomized.